| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $11,992,497 | 32 | 100 |
| Markus Richard | Chief Medical Officer | 0 | $0 | 2 | $210,144 | $-210,144 |
| Tang Carolyn C. | General Counsel | 0 | $0 | 2 | $318,496 | $-318,496 |
| Azoy Alexander | Chief Accounting Officer | 0 | $0 | 6 | $395,667 | $-395,667 |
| Goeltz II Robert C. | Chief Financial Officer | 0 | $0 | 5 | $755,891 | $-755,891 |
| ROSEN TERRY J | Chief Executive Officer | 0 | $0 | 2 | $1.2M | $-1.2M |
| Jarrett Jennifer | Chief Operating Officer | 0 | $0 | 3 | $1.42M | $-1.42M |
| Jaen Juan C. | President | 0 | $0 | 12 | $7.69M | $-7.69M |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in …
Over the last 12 months, insiders at Arcus Biosciences, Inc. have bought $0 and sold $11.99M worth of Arcus Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Arcus Biosciences, Inc. have bought $118.29M and sold $4.79M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 19,800 shares for transaction amount of $201,465 was made by ROSEN TERRY J (Chief Executive Officer) on 2025‑02‑27.
| 2026-08-21 | Sale | Azoy Alexander | Chief Accounting Officer | 2,827 0.0022% | $30.00 | $84,810 | -18.75% | |
| 2026-07-10 | Sale | Jaen Juan C. | President | 19,799 0.0195% | $28.61 | $566,410 | -7.09% | |
| 2026-07-10 | Sale | Jaen Juan C. | President | 20,067 0.0197% | $28.62 | $574,288 | -7.09% | |
| 2026-07-09 | Sale | Jaen Juan C. | President | 48,502 0.0483% | $30.05 | $1.46M | -10.01% | |
| 2026-06-24 | Sale | Jaen Juan C. | President | 6,431 0.0067% | $29.66 | $190,740 | -3.02% | |
| 2026-06-23 | Sale | Jaen Juan C. | President | 15,764 0.0154% | $27.73 | $437,100 | -0.57% | |
| 2026-06-22 | Sale | Jaen Juan C. | President | 9,236 0.0091% | $27.03 | $249,661 | +2.99% | |
| 2026-06-01 | Sale | Azoy Alexander | Chief Accounting Officer | 2,562 0.0026% | $25.77 | $66,024 | +5.03% | |
| 2026-05-11 | Sale | Goeltz II Robert C. | Chief Financial Officer | 7,763 0.008% | $25.63 | $198,966 | +3.58% | |
| 2026-01-05 | Sale | Jaen Juan C. | President | 31,823 0.029% | $21.41 | $681,342 | +11.07% | |
| 2025-12-31 | Sale | Goeltz II Robert C. | Chief Financial Officer | 6,552 0.0061% | $23.38 | $153,186 | +1.26% | |
| 2025-12-18 | Sale | Azoy Alexander | Chief Accounting Officer | 4,343 0.0041% | $22.25 | $96,614 | +9.00% | |
| 2025-12-17 | Sale | ROSEN TERRY J | Chief Executive Officer | 25,744 0.0237% | $22.16 | $570,474 | +7.52% | |
| 2025-12-17 | Sale | Jaen Juan C. | President | 9,983 0.0092% | $22.16 | $221,218 | +7.52% | |
| 2025-12-17 | Sale | Jarrett Jennifer | Chief Operating Officer | 9,983 0.0092% | $22.16 | $221,218 | +7.52% | |
| 2025-12-17 | Sale | Tang Carolyn C. | General Counsel | 6,810 0.0063% | $22.16 | $150,906 | +7.52% | |
| 2025-12-17 | Sale | Goeltz II Robert C. | Chief Financial Officer | 5,960 0.0055% | $22.16 | $132,071 | +7.52% | |
| 2025-12-17 | Sale | Markus Richard | Chief Medical Officer | 4,494 0.0041% | $22.16 | $99,585 | +7.52% | |
| 2025-12-17 | Sale | Azoy Alexander | Chief Accounting Officer | 2,113 0.0019% | $22.16 | $46,823 | +7.52% | |
| 2025-12-16 | Sale | ROSEN TERRY J | Chief Executive Officer | 28,947 0.0264% | $21.88 | $633,485 | +7.84% |
| ROSEN TERRY J | Chief Executive Officer | 2194809 1.7451% | $41.5M | 22 | 8 | <0.0001% |
| Jaen Juan C. | President | 822240 0.6537% | $15.55M | 8 | 24 | <0.0001% |
| Goeltz II Robert C. | Chief Financial Officer | 84161 0.0669% | $1.59M | 1 | 12 | +33.11% |
| GILEAD SCIENCES, INC. | 10 percent owner | 31424760 24.9853% | $594.24M | 4 | 0 | <0.0001% |
| FALBERG KATHRYN E | director | 102106 0.0812% | $1.93M | 7 | 0 | +8.71% |
| KANEKO YASUNORI | director | 28400 0.0226% | $537,044.00 | 2 | 0 | <0.0001% |
| Grossman William | Chief Medical Officer | 20723 0.0165% | $391,871.93 | 3 | 5 | +93.38% |
$21,345,882 | 83 | 94.45% | $2.19B | |
$52,263,649 | 70 | 1.18% | $2.49B | |
Arcus Biosciences, Inc. (RCUS) | $586,486,795 | 47 | 4.28% | $2.38B |
$154,047,855 | 36 | 79.21% | $2.21B | |
$28,907,358 | 35 | 41.41% | $2.28B |
| Increased Positions | 146 | +89.57% | 31M | +31.08% |
| Decreased Positions | 68 | -41.72% | 9M | -9.43% |
| New Positions | 51 | New | 14M | New |
| Sold Out Positions | 30 | Sold Out | 4M | Sold Out |
| Total Postitions | 241 | +47.85% | 122M | +21.64% |
| Gilead Sciences, Inc. | $731,883.00 | 25.76% | 31.42M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $275,075.00 | 9.68% | 11.81M | +352,887 | +3.08% | 2025-09-30 |
| Vanguard Group Inc | $154,400.00 | 5.43% | 6.63M | +73,210 | +1.12% | 2025-09-30 |
| Point72 Asset Management, L.P. | $100,903.00 | 3.55% | 4.33M | -2M | -27.39% | 2025-09-30 |
| Woodline Partners Lp | $87,796.00 | 3.09% | 3.77M | -230,345 | -5.76% | 2025-09-30 |
| Suvretta Capital Management, Llc | $85,914.00 | 3.02% | 3.69M | 0 | 0% | 2025-09-30 |
| State Street Corp | $79,066.00 | 2.78% | 3.39M | -235,961 | -6.5% | 2025-09-30 |
| Siren, L.L.C. | $67,822.00 | 2.39% | 2.91M | +1M | +80.64% | 2025-09-30 |
| Fmr Llc | $53,474.00 | 1.88% | 2.3M | -277,273 | -10.78% | 2025-09-30 |
| Geode Capital Management, Llc | $37,227.00 | 1.31% | 1.6M | +2,080 | +0.13% | 2025-09-30 |